Tuesday, 22 July 2014
Last updated 5 hours ago
Jul 31 2009 | 9:46am ET
Alternative investments firm Signal Capital Management has named a biotech expert as executive and academic vice chairman.
Roger van Hanwehr is CEO of energy technology development company Solus and co-founder of consulting firm Arcxeon. He also teaches biotechnology at Georgetown University in Washington, D.C.
Hanwehr, a polymath with expertise in such diverse fields as biological and radiological defense, renewable energy and nanotechnology, will evaluate investment opportunities in his new role at Signal.
Jul 8 2014 | 10:48am ET
The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…